Making Clots and Breaking Clots: Modelling Arterial Occlusion to Test Stroke Sonothrombolysis

Amelia Tomkins
BBiomedSci (Hons)

Thesis by publication submitted for the degree of Doctor of Philosophy (Human Physiology)
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine
University of Newcastle

October 2015
STATEMENT OF ORIGINALITY

The thesis contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. I give consent to the final version of my thesis being made available worldwide when deposited in the University’s Digital Repository*, subject to the provisions of the Copyright Act 1968. * Unless an embargo has been approved for the determined period.

STATEMENT OF COLLABORATION

I hereby certify that the work embodied in this thesis has been done in collaboration with other researchers, and carried out in other institutions. I have included as part of the thesis a statement clearly outlining the extent of collaboration, with whom and under what auspices.

See Appendix A.

STATEMENT OF AUTHORSHIP

I hereby certify that the work embodied in this thesis contains published papers of which I am a joint author. I have included as part of the thesis a written statement, endorsed by my supervisor, attesting to my contribution to the joint publications.

See Appendix A.

________________________________________  ________________________
Amelia Tomkins     Date
ACKNOWLEDGEMENTS

As with any project, there are many people who have contributed to making this thesis and this PhD project possible. From my supervisors, colleagues and research support staff, to my friends and family on the sidelines encouraging me to go on. To all these people I wish to say thank you. Without you, this PhD would not have happened.

My supervisors…

I would like to say a big thank you to my supervisors, Associate Professor Neil Spratt and Professor Chris Levi, for helping develop this project and for providing insight, support and guidance as it progressed and, inevitably, changed track. To my primary supervisor, Neil, I would like to say thanks for giving me a job back in 2007. That first research position has led me down many interesting avenues and taught me so much about study design, research practice, and problem solving! I have learnt a lot in 8 years and the progression from research assistant to honours student to PhD student has taught me a lot; not just about research but also about myself and my career aspirations.

My colleagues and co-authors…

Thank you to the translational stroke research team (“Spratt Lab”) at the University of Newcastle, past and present: Debbie Pepperall, Lucy Murtha, Rebecca Hood, Caitlin Logan, Daniel Beard, Phoebe Chung, Damian McLeod, Sarah McCann. Thank you for technical expertise and assistance, and for reading through paper drafts and thesis drafts and providing me with helpful feedback. Particular thanks to Debbie for her constant support and encouragement and her histological expertise. Also a huge thanks to Rebecca, whose assistance with the carotid artery surgeries were instrumental in finalising the experimental portions of the project. And finally, thanks to Lucy and Caitlin for helping out at the home stretch.

Thank you to the stroke research team at Justus-Liebig Universität, Giessen, Germany: Max Nedelmann, Nadine Schleicher, Mesut Yeniguen, Tibo Gerriets, Sabrina Kastaun and Martin Juenemann and Manfred Kaps. Thank you for welcoming me in to your group for 12 months. A big thanks to Associate Professor Max Nedelmann for supporting this collaboration and providing me with the opportunity to learn new skills and techniques. Also a big thanks to Nadine Schleicher for sharing her lab space with me and being patient with my broken German! Additionally, I would like to acknowledge the help of Marian Kampschulte and Guhnild Martels in the Department of Radiology at Justus-Liebig Universität, for their technical assistance with the micro-CT.
**My funding sources…**

I would like to acknowledge the financial support I received during this PhD. I was awarded a post-graduate scholarship by the National Heart Foundation, co-funded by the National Stroke Foundation. Additionally, I would like to thank Jennie Thomas for her generous scholarship that provided me with the means to travel to and live in Germany. I would also like to thank Jennie for her continuing support and interest in my research career.

**My friends and family…**

Thank you to all my close friends who have provided support through the highs and lows and in particular, Belinda Hayman, Nicole Adams, and Lorraine Lynch.

Thanks to all my family for your constant support and encouragement. In particular, a huge thanks to my parents for putting a roof over my head, feeding me and constantly encouraging me along the way. Your love and support throughout my life has made me who I am and has helped me to achieve such amazing things! Thank you.

**My other half…**

And finally to my wonderful Pat. Your love, support and encouragement has helped me reach the end of this journey. I consider myself so lucky everyday to have you by my side. Thank you!
CONTENTS

Declarations....................................................................................................................... i
Acknowledgements........................................................................................................ ii
Contents............................................................................................................................... iv
List of Figures and Tables................................................................................................... vii
Abbreviations................................................................................................................... ix
Clinical trials referenced in this thesis................................................................................ x
Abstract ............................................................................................................................ 1

Chapter 1

Introduction ....................................................................................................................... 4
  1.1. Stroke.................................................................................................................... 5
  1.2. Sonothrombolysis.................................................................................................. 17
  1.3. Animal models for preclinical stroke research..................................................... 25
  1.4. Aims and rationale................................................................................................. 36

Chapter 2

Microbubble-enhanced sonothrombolysis of middle cerebral artery occlusion............ 38
  2.1. Study aims, rationale and hypotheses.................................................................... 39
  Publication: Platelet rich clots are resistant to lysis by thrombolytic therapy in a rat model of embolic stroke................................................................. 41
  2.2. Abstract.............................................................................................................. 42
  2.3. Background......................................................................................................... 43
  2.4. Methods............................................................................................................. 43
  2.5. Results............................................................................................................... 48
  2.6. Discussion.......................................................................................................... 53
  2.7. Conclusion......................................................................................................... 55
  2.8. Additional information....................................................................................... 56
Chapter 3
Microbubble-enhanced sonothrombolysis of microvascular occlusion

3.1. Study aims, rationale and hypotheses

Publication: Sonothrombolysis with BR38 microbubbles improves microvascular patency in a rat model of stroke

3.2. Abstract

3.3. Introduction

3.4. Methods

3.5. Results

3.6. Discussion

3.7. Additional information

Chapter 4
Sonothrombolysis of extracranial carotid artery occlusion with variable stenosis

4.1. Study aims, rationale and hypotheses

Publication: Thrombolytic recanalization of carotid arteries is highly dependent on degree of stenosis, despite sonothrombolysis

4.2. Abstract

4.3. Background

4.4. Methods

4.5. Results

4.6. Discussion

4.7. Additional information

Chapter 5
tPA for preclinical stroke research

5.1. Study aims, rationale and hypotheses

Publication: Tissue plasminogen activator for preclinical stroke research: Neither “rat” nor “human” dose mimics clinical recanalization in a carotid occlusion model

5.2. Abstract

5.3. Introduction

5.4. Results

5.5. Discussion

5.6. Methods

5.7. Additional information
LIST OF FIGURES AND TABLES

Chapter 1

Figure 1-1 Ischaemic core and penumbra progression .................................................. 6
Figure 1-2 Platelet activation ......................................................................................... 9
Figure 1-3 Clotting cascade .......................................................................................... 10
Figure 1-4 Thrombolysis with tissue plasminogen activator ........................................ 13
Figure 1-5 Microvascular occlusion .............................................................................. 15
Figure 1-6 Mechanisms of sonothrombolysis ............................................................... 18
Figure 1-7 The most common preclinical models of stroke ......................................... 27
Figure 1-8 Clot delivery to the middle cerebral artery .................................................... 28
Figure 1-9 Decision tree of different experimental clot preparations .......................... 29
Figure 1-10 Histopathological composition of thrombi from stroke patients .......... 30
Figure 1-11 Fibrin fibre thickness .................................................................................. 31
Figure 1-12 Fibrin structure of platelet poor and platelet rich clots ............................... 33

Chapter 2

Table 2-1 Experimental protocols ................................................................................. 44
Figure 2-1 Visualisation of vascular filling and clot presence (Study 2) ....................... 47
Figure 2-2 Laser Doppler flowmetry and infarction following middle cerebral artery occlusion with platelet rich clots (Study 1) ......................................................... 49
Figure 2-3 Laser Doppler flowmetry (LDF) of regional cerebral blood flow in treatment groups (Study 2) .............................................................................. 50
Figure 2-4 Vascular filling and clot presence (Study 2) ................................................... 50-52
Chapter 3

Table 3-1 Properties of SonoVue® and BR38 microbubbles

Figure 3-1 Experimental timeline

Figure 3-2 Micro-CT scan for vascular volume

Figure 3-3 Vascular volume of the ipsilateral hemisphere

Figure 3-4 Nano-CT scan of cortex

Figure 3-5 Volume of ischemic lesion

Chapter 4

Figure 4-1 Experimental timeline [A] and surgery schematic [B] of carotid artery occlusion with stenosis

Figure 4-2 Example flow trace of crush, occlusion and recanalization

Figure 4-3 Carotid artery recanalization in the setting of mild or severe stenosis

Chapter 5

Figure 5-1 Recanalization rates at varying doses of tPA

Figure 5-2 Time to sustained recanalization

Figure 5-3 Doppler flow of crush and occlusion with recanalization

Appendix C

Figure C-1 Systematic review of preclinical embolic stroke models: studies retrieved to date
ABBREVIATIONS

Please note, this thesis uses British English unless directly citing a paper or clinical trial name.

ACA   Anterior cerebral artery
ACEC  Animal Care and Ethics Committee
AIC   Acute ischaemic changes
BPU   Blood perfusion units (for laser Doppler flowmetry)
CCA   Common carotid artery
CT    Computed Tomography
ECA   External carotid artery
GP IIb/IIIa Platelet glycoprotein IIb/IIIa receptor
HU    Hounsfield units
Hz    Hertz
ICA   Internal carotid artery
JLU   Justus-Liebig University, Giessen, Germany
kHz   Kilohertz
LDF   Laser doppler flowmetry
MCA   Middle cerebral artery
mg/kg Milligrams per kilogram of body weight
MHz   Megahertz
MRI   Magnetic resonance imaging
mRS   Modified Rankin Scale
mW/cm² Milliwatts per square centimetre
NIHSS National Institute of Health Stroke Score
o.d.  Outer diameter
PAI-1 Plasminogen inhibitor-I
PRC   Platelet rich clot
RBC   Red blood cell
rCBF  Regional cerebral blood flow
ROI   Region of Interest
SAH   Subarachnoid haemorrhage
SD    Standard deviation
SHR   Spontaneously hypertensive rat
sICH  Symptomatic intracerebral haemorrhage
TCCD or TCCS Transcranial color-coded Doppler/sonography
TCD   Transcranial Doppler ultrasound

tPA or rt-PA   (Recombinant) tissue plasminogen activator

TTC   2,3,5-triphenyl-tetrazolium chloride

U/S   Ultrasound

UoN   University of Newcastle, Australia

VV   Vascular volume

VVF   Vascular volume fraction

**CLINICAL TRIALS REFERENCED IN THIS THESIS**

*Clinical trial names are defined in footnotes at first mention throughout the text.*

- **CLOTBUST** Combined Lysis Of Thrombus in Brain ischaemia using transcranial Ultrasound and Systemic tPA (Clinical sonothrombolysis Trial)
- **CLOTBUST-ER** Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke
- **ECASS III** European Cooperative Acute Stroke Study III
- **ESCAPE** Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion with Emphasis on Minimizing CT to Recanalization Times
- **EXTEND-IA** Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial
- **MR CLEAN** Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands
- **NINDS** National Institute of Neurological Disorders and Stroke rtPA Stroke study
- **REVASCAT** RandomizEd Trial of reVascularizAtion With Solitaire FR® Device Versus Best mediCal Therapy in the Treatment of Acute Stroke Due to anTerior Circulation Large Vessel Occlusion Presenting Within 8 Hours of Symptom Onset
- **SWIFT-PRIME** Solitaire With the Intention For Thrombectomy as PRIMary Endovascular Treatment
- **TRUMBI** TRanscranial low-frequency Ultrasound-Mediated thrombolysis in Brain Ischemia (Clinical sonothrombolysis Trial)
- **TUCSON** Transcranial Ultrasound in Clinical Sonothrombolysis (Clinical sonothrombolysis Trial)
Abstract

Background: Acute ischaemic stroke is caused by occlusion of a major cerebral artery and is a major cause of death and disability worldwide. Early reopening of the occluded artery (recanalization) to restore blood flow to the ischaemic tissue is the best known approach to improving patient outcome after stroke. However, the current approved thrombolytic drug, tissue plasminogen activator (tPA), causes recanalization in <50% of cases treated, indicating a need for better recanalization approaches. Recent studies have revealed benefit of endovascular intervention to remove the occluding clot, but with limited endovascular centres, improving tPA’s effect may be a better and more cost effective approach for most centres. One such approach to enhanced tPA recanalization is with the application of continuous ultrasound insonation during tPA infusion (sonothrombolysis). Small scale trials of sonothrombolysis for stroke have shown improved recanalization and patient outcome over tPA alone. Added infusion of microbubbles has also been suggested to enhance sonothrombolysis. However, much is still unknown regarding sonothrombolysis efficacy in different situations of stroke and in preclinical models of clinically relevant scenarios. Clinical trials of sonothrombolysis have thus far focused on intracranial large vessel occlusions. However, stroke is a heterogeneous condition whereby patient outcome is affected by clot compositions, the occlusion site, and vascular stenosis. Efforts to model the clinical situation have also resulted in a large variety of experimental clots used for preclinical thrombolytic testing. Preclinical studies of sonothrombolysis to-date have tended to use models with clot compositions that are more susceptible to thrombolysis than a more clinically common platelet rich clot (PRC) composition. The effect of sonothrombolysis on PRC is yet to be tested in vivo. The middle cerebral artery (MCA) is the most commonly affected vessel in stroke, yet occlusions of the internal carotid artery (ICA), often associated with vascular stenosis, are associated with poorer patient outcome and lower rates of tPA recanalization. The recanalization potential of sonothrombolysis for extracranial carotid occlusions has not previously been tested, nor the effect of varying degrees of stenosis underlying an occlusion. While recanalization of the large occluded arteries is known to be a predictor of good patient outcome, reperfusion of the ischemic tissue has recently been shown to be a better predictor of good outcome than recanalization. Perfusion deficits caused by occlusions of the microvasculature can persist even after recanalization due fibrin and platelet deposits causing a “no-reflow phenomenon”. Improving therapies to target not only large vessel recanalization, but also microvascular reperfusion should improve the overall rates of patient outcome after stroke. To date, there has only been one preclinical study of sonothrombolysis of the microvasculature that suggested a benefit of this therapy for stroke reperfusion. Sonothrombolysis ± microbubbles may therefore, be a potential therapy to target both large vessel recanalization and microvascular reperfusion.
obtain meaningful data of the potential of sonothrombolysis for stroke, it needs to be compared against the current standard, tPA. Rodent doses of tPA are conventionally 10-fold higher than human doses, due to some evidence that the rat fibrinolytic system is less sensitive than humans. However in some models, this dose causes high rates of recanalization that are not representative of the clinical response to thrombolysis. An appropriate “human equivalent” tPA dose that models the clinical response and allows room for improvement with sonothrombolysis is not known.

**Aims:** The overall aim of this thesis was to test sonothrombolysis (± microbubbles) for recanalization in different models of stroke in rats. The individual aims of the studies were: 1) To develop a model of MCA occlusion with PRC and to test for recanalization with sonothrombolysis and microbubbles (Chapter 2), 2) To test the effect of sonothrombolysis with microbubbles on restoring microvascular patency after large vessel recanalization and to directly compare two microbubble formulations at high and low doses (Chapter 3), 3) To develop a model of extracranial carotid artery occlusion with variable stenosis and to test sonothrombolysis for recanalization in this model (Chapter 4), and 4) To compare different doses of tPA ranging from the clinical dose (0.9 mg/kg) to the conventional rat dose (10 mg/kg) in a model of carotid artery occlusion to identify a “human equivalent” tPA dose that mimics clinical recanalization rates (Chapter 5).

**Methods:** 1) Preformed PRC were injected via the extracranial carotid arteries to occlude the origin of the MCA. Treatment groups were sonothrombolysis with microbubbles (BR38), tPA alone, or control. Recanalization was monitored by laser Doppler flowmetry and macroscopic visualization of the cerebral vasculature post-mortem. 2) Microvascular occlusion was achieved in a model of thread occlusion of the MCA with recanalization. Treatment groups were sonothrombolysis with SonoVue or BR38 microbubbles at full or half doses, tPA alone, or saline control. Patency of the microvasculature was assessed by micro-computed tomography. 3) The carotid artery was crushed to injure the endothelium and stenosed with a ligature to induce local thrombosis. Following occlusion, the stenotic ligature was released for a model of mild stenosis, or left in place for a model of severe stenosis. Doppler flow was used to confirm occlusion and to monitor for recanalization. Treatment groups were sonothrombolysis or tPA-alone in both stenosis models. 4) The mild stenosis model was used for testing the recanalization rates of different tPA doses, monitored by Doppler flow. tPA doses were: clinical dose (0.9 mg/kg), 2x the clinical dose (1.8 mg/kg), 5x the clinical dose (4.5 mg/kg), or the conventionally used rat dose (10 mg/kg).

**Results:** 1) No recanalization was observed in any treatment group (sonothrombolysis with microbubbles, tPA or control) in a model of MCA occlusion with PRC. 2) Microvascular patency was restored by sonothrombolysis with microbubbles after large vessel recanalization, regardless
of microbubble formulation or dosage. tPA alone did not restore microvascular patency. 3) High rates of recanalization were observed in a model of carotid artery occlusion with a mild stenosis, regardless of treatment: sonothrombolysis or tPA alone. No recanalization was observed in the severe stenosis model, regardless of treatment. 4) The clinical tPA dose did not cause recanalization, and the conventional rat dose caused recanalization rates too high to mimic clinical recanalization in a carotid artery occlusion model. In this model, 1.8 mg/kg tPA (2x the clinical dose) more closely mimicked recanalization rates of clinical carotid artery occlusion.

**Conclusions:** My results raise doubts regarding the overall efficacy of sonothrombolysis (± microbubbles) as a recanalization therapy for stroke. In different models of stroke, I determined that characteristics of clot composition and vessel stenosis will affect the success of thrombolysis (and sonothrombolysis). PRC were found to be completely resistant to microbubble-enhanced sonothrombolysis. My results suggest that sonothrombolysis will not be beneficial for this subpopulation of stroke patients. The degree of carotid artery stenosis associated with an occlusion was found to be predictive of thrombolytic success. My study was inconclusive regarding sonothrombolysis for recanalization in a model of mild stenosis and occlusion due to high recanalization rates with tPA alone. Sustained recanalization with any thrombolytic or thrombolytic-enhancer is unlikely to occur in the presence of a severe stenosis. Sonothrombolysis with microbubbles restored microvascular perfusion after mechanical recanalization of the large vessel occlusion. This effect was regardless of microbubble formulation or dose, suggesting a class effect of microbubbles to enhance sonothrombolysis, rather than individual microbubble properties or concentration. With recent evidence that reperfusion is a better predictor of good outcome than recanalization, microbubble-enhanced sonothrombolysis of microvascular occlusion is a potential approach to enhance the reperfusion clinically. Finally, the conventional tPA doses (human and rat) used preclinically, were found to be poor mimics of clinical recanalization rates in a model of carotid artery occlusion. For any thrombolytic-enhancer therapies, recanalization is an important outcome measure as it is the main mechanism by which tPA causes good patient outcome (by clot lysis and flow restoration). Using doses that mimic clinical recanalization rates may allow better translation of therapies. This finding should be considered for any future testing of thrombolytic-enhancers. Overall, this thesis presents data to indicate that sonothrombolysis (± microbubbles) is unlikely to be a suitable enhancer of tPA for large artery recanalization in stroke patients. However, there could be a potential for this strategy as an enhancer of reperfusion to improve patient outcome.